In Med Pharmaceuticals Inc. - Understand $inm stock

$INM Market Cap: $3.236 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$4.961M

TTM

Gross Margin

31.54%

TTM

Net Earnings

-$6.817M

TTM

Current Assets

$7.280M

Q3 2024

Current Liabilities

$1.436M

Q3 2024

Current Ratio

507.0%

Q3 2024

Total Assets

$10.47M

Q3 2024

Total Liabilities

$2.070M

Q3 2024

Book Value

$8.395M

Q3 2024

Cash

$5.583M

Q3 2024

P/E

-0.4747

Nov 29, 2024 EST

Free Cash Flow

-$8.857M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000
Revenue	$4.598M	$4.136M	$1.089M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$40.00K	$80.00K	$170.0K	$630.0K	$780.0K	$2.640M	$4.150M	$2.080M	$170.0K	$10.00K	$0.00	$0.00
YoY Change	11.18%	279.61%											-100.0%	-50.0%	-52.94%	-73.02%	-19.23%	-70.45%	-36.39%	99.52%	1123.53%	1600.0%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000
Revenue	$4.598M	$4.136M	$1.089M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$40.00K	$80.00K	$170.0K	$630.0K	$780.0K	$2.640M	$4.150M	$2.080M	$170.0K	$10.00K	$0.00	$0.00
Cost Of Revenue	$3.497M	$2.424M	$545.9K										$0.00	$30.00K	$10.00K	$110.0K	$410.0K	$300.0K	$1.790M	$3.130M	$1.190M	$80.00K	$20.00K	$20.00K	$10.00K
Gross Profit	$1.101M	$1.403M	$543.5K										$0.00	$10.00K	$70.00K	$60.00K	$220.0K	$480.0K	$850.0K	$1.020M	$890.0K	$90.00K	$0.00	-$10.00K	-$10.00K
Gross Profit Margin	23.94%	33.93%	49.89%											25.0%	87.5%	35.29%	34.92%	61.54%	32.2%	24.58%	42.79%	52.94%	0.0%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000
Selling, General & Admin	$5.251M	$5.850M	$6.667M	$4.479M	$3.560M	$5.950M	$5.170M	$2.740M	$1.440M	$2.770M	$1.090M	$50.00K	$150.0K	$280.0K	$300.0K	$530.0K	$1.120M	$1.200M	$1.350M	$2.190M	$1.610M	$600.0K	$640.0K	$2.110M	$2.410M
YoY Change	-10.24%	-12.25%	48.84%	25.82%	-40.17%	15.09%	88.69%	90.28%	-48.01%	154.13%	2080.0%	-66.67%	-46.43%	-6.67%	-43.4%	-52.68%	-6.67%	-11.11%	-38.36%	36.02%	168.33%	-6.25%	-69.67%	-12.45%
% of Gross Profit	476.94%	416.95%	1226.58%											2800.0%	428.57%	883.33%	509.09%	250.0%	158.82%	214.71%	180.9%	666.67%
Research & Development	$3.765M	$3.732M	$7.283M	$5.338M	$5.810M		$1.520M	$560.0K	$290.0K	$800.0K	$60.00K	$0.00	$20.00K	$0.00	$120.0K	$120.0K	$240.0K	$190.0K	$390.0K				$0.00	$310.0K	$860.0K
YoY Change	0.88%	-48.75%	36.43%	-8.12%			171.43%	93.1%	-63.75%	1233.33%		-100.0%		-100.0%	0.0%	-50.0%	26.32%	-51.28%					-100.0%	-63.95%
% of Gross Profit	341.99%	266.0%	1339.83%											0.0%	171.43%	200.0%	109.09%	39.58%	45.88%
Depreciation & Amortization	$219.6K	$202.2K	$185.7K	$120.9K	$160.0K	$90.00K	$90.00K	$70.00K	$70.00K	$80.00K	$0.00		$0.00	$130.0K	$70.00K	$170.0K	$80.00K	$160.0K	$250.0K	$440.0K	$290.0K	$360.0K	$1.860M	$2.230M	$430.0K
YoY Change	8.58%	8.94%	53.6%	-24.46%	77.78%	0.0%	28.57%	0.0%	-12.5%				-100.0%	85.71%	-58.82%	112.5%	-50.0%	-36.0%	-43.18%	51.72%	-19.44%	-80.65%	-16.59%	418.6%
% of Gross Profit	19.95%	14.42%	34.16%											1300.0%	100.0%	283.33%	36.36%	33.33%	29.41%	43.14%	32.58%	400.0%
Operating Expenses	$9.297M	$9.782M	$17.81M	$9.938M	$9.030M	$10.31M	$6.780M	$3.370M	$1.790M	$3.660M	$1.150M	$50.00K	$170.0K	$410.0K	$490.0K	$820.0K	$1.430M	$1.550M	$1.980M	$2.970M	$2.120M	$1.130M	$2.770M	$6.160M	$4.140M
YoY Change	-4.95%	-45.07%	79.18%	10.06%	-12.42%	52.06%	101.19%	88.27%	-51.09%	218.26%	2200.0%	-70.59%	-58.54%	-16.33%	-40.24%	-42.66%	-7.74%	-21.72%	-33.33%	40.09%	87.61%	-59.21%	-55.03%	48.79%
Operating Profit	-$8.196M	-$7.948M	-$18.60M	-$10.20M									-$170.0K	-$400.0K	-$420.0K	-$760.0K	-$1.210M	-$1.070M	-$1.130M	-$1.950M	-$1.230M	-$1.040M	-$2.770M	-$6.170M	-$4.150M
YoY Change	3.13%	-57.27%	82.3%										-57.5%	-4.76%	-44.74%	-37.19%	13.08%	-5.31%	-42.05%	58.54%	18.27%	-62.45%	-55.11%	48.67%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000
Interest Expense	$466.0K	$440.0K	-$21.46K	$95.54K	$190.0K	$290.0K	$70.00K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$10.00K	-$20.00K	-$20.00K	-$30.00K	-$100.0K	-$80.00K	-$30.00K	-$10.00K	$50.00K	$70.00K	-$90.00K	-$70.00K
YoY Change	5.9%	-2150.33%	-122.46%	-49.72%	-34.48%	314.29%							-100.0%	-150.0%	0.0%	-33.33%	-70.0%	25.0%	166.67%	200.0%	-120.0%	-28.57%	-177.78%	28.57%
% of Operating Profit
Other Income/Expense, Net	$527.9K	$431.2K	-$1.314M	-$360.4K						$0.00	$0.00		$0.00	$70.00K	$100.0K	$240.0K	$0.00	$0.00
YoY Change	22.44%	-132.81%	264.73%										-100.0%	-30.0%	-58.33%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000
Pretax Income	-$7.668M	-$7.935M	-$18.60M	-$10.20M	-$8.840M	-$10.01M	-$6.710M	-$3.370M	-$1.790M	-$3.660M	-$1.150M	-$50.00K	-$170.0K	-$310.0K	-$330.0K	-$1.060M	-$1.530M	-$1.170M	-$1.220M	-$2.720M	-$1.510M	-$1.160M	-$2.740M	-$4.290M	-$4.210M
YoY Change	-3.35%	-57.34%	82.3%	15.42%	-11.69%	49.18%	99.11%	88.27%	-51.09%	218.26%	2200.0%	-70.59%	-45.16%	-6.06%	-68.87%	-30.72%	30.77%	-4.1%	-55.15%	80.13%	30.17%	-57.66%	-36.13%	1.9%
Income Tax	$7.100K	$13.10K									$0.00	$0.00	$20.00K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$7.700M	-$7.948M	-$18.60M	-$10.20M	-$8.840M	-$10.01M	-$6.710M	-$3.370M	-$1.790M	-$3.660M	-$1.150M	-$50.00K	-$190.0K	-$310.0K	-$330.0K	-$1.060M	-$930.0K	-$1.760M	-$1.220M	-$2.720M	-$1.510M	-$1.160M	-$2.740M	-$4.290M	-$4.210M
YoY Change	-3.12%	-57.27%	82.3%	15.42%	-11.69%	49.18%	99.11%	88.27%	-51.09%	218.26%	2200.0%	-73.68%	-38.71%	-6.06%	-68.87%	13.98%	-47.16%	44.26%	-55.15%	80.13%	30.17%	-57.66%	-36.13%	1.9%
Net Earnings / Revenue	-167.47%	-192.18%	-1707.32%											-775.0%	-412.5%	-623.53%	-147.62%	-225.64%	-46.21%	-65.54%	-72.6%	-682.35%	-27400.0%
Basic Earnings Per Share	-$1.01	-$3.25	-$33.17	-$37.96
Diluted Earnings Per Share	-$1.01	-$3.25	-$33.17	-$1.518M	-$1.693M	-$1.929M	-$1.553M	-$1.150M	-$983.5K	-$2.614M	-$1.095M	-$49.02K	-$186.3K	-$704.5K	-$2.750M	-$11.78M	-$11.63M	-$29.33M	-$30.50M	-$90.67M	-$151.0M	-$116.0M	-$274.0M	-$429.0M	-$1.912B

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000
Cash & Short-Term Investments	$6.615M	$8.960M	$6.222M	$7.410M	$5.850M	$13.78M	$20.17M	$5.170M	$40.00K	$130.0K	$10.00K	$0.00	$40.00K	$230.0K	$0.00	$0.00	$50.00K	$130.0K	$50.00K	$0.00	$10.00K	$80.00K	$660.0K	$2.190M	$1.210M
YoY Change	-26.18%	44.01%	-16.03%	26.66%	-57.55%	-31.68%	290.14%	12825.0%	-69.23%	1200.0%		-100.0%	-82.61%			-100.0%	-61.54%	160.0%		-100.0%	-87.5%	-87.88%	-69.86%	80.99%
Cash & Equivalents	$6.572M	$8.910M	$6.177M	$7.363M	$5.810M	$9.830M	$18.38M	$5.170M	$40.00K	$130.0K	$10.00K	$0.00	$40.00K	$230.0K	$0.00	$0.00	$50.00K	$130.0K	$50.00K	$0.00	$10.00K	$50.00K	$0.00	$40.00K	$110.0K
Short-Term Investments	$43.06K	$40.00K	$44.80K	$46.46K	$40.00K	$3.950M	$1.780M														$0.00	$30.00K	$650.0K	$2.140M	$1.100M
Other Short-Term Assets	$477.8K	$500.0K	$797.2K	$956.8K	$420.0K	$320.0K	$150.0K	$140.0K	$40.00K	$40.00K	$160.0K	$0.00	$0.00	$0.00	$10.00K	$0.00	$10.00K	$20.00K	$0.00	$10.00K	$20.00K	$20.00K	$20.00K	$40.00K	$110.0K
YoY Change	-4.45%	-37.28%	-16.67%	127.8%	31.25%	113.33%	7.14%	250.0%	0.0%	-75.0%				-100.0%		-100.0%	-50.0%		-100.0%	-50.0%	0.0%	0.0%	-50.0%	-63.64%
Inventory	$1.244M	$1.620M	$2.491M														$0.00	$10.00K	$0.00	$0.00	$10.00K	$110.0K	$0.00
Prepaid Expenses
Receivables	$352.8K	$260.0K	$88.03K	$11.92K	$50.00K	$60.00K	$40.00K	$50.00K	$70.00K	$30.00K	$20.00K	$0.00	$0.00	$20.00K	$0.00	$0.00	$180.0K	$210.0K	$410.0K	$610.0K	$210.0K	$200.0K	$30.00K	$140.0K	$0.00
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$20.00K	$350.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$320.0K	$0.00	$0.00
Total Short-Term Assets	$8.690M	$11.33M	$9.598M	$8.378M	$6.310M	$14.17M	$20.36M	$5.360M	$150.0K	$200.0K	$190.0K	$10.00K	$50.00K	$250.0K	$10.00K	$20.00K	$590.0K	$360.0K	$460.0K	$630.0K	$250.0K	$420.0K	$1.020M	$2.370M	$1.330M
YoY Change	-23.3%	18.05%	14.56%	32.78%	-55.47%	-30.4%	279.85%	3473.33%	-25.0%	5.26%	1800.0%	-80.0%	-80.0%	2400.0%	-50.0%	-96.61%	63.89%	-21.74%	-26.98%	152.0%	-40.48%	-58.82%	-56.96%	78.2%
Property, Plant & Equipment	$1.250M	$720.0K	$904.3K	$326.6K	$400.0K	$40.00K	$40.00K	$20.00K	$0.00	$10.00K	$0.00				$0.00	$0.00	$110.0K	$30.00K	$30.00K	$100.0K	$80.00K	$50.00K	$340.0K	$2.290M	$2.510M
YoY Change	73.61%	-20.38%	176.87%	-18.35%	900.0%	0.0%	100.0%		-100.0%							-100.0%	266.67%	0.0%	-70.0%	25.0%	60.0%	-85.29%	-85.15%	-8.76%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$100.0K	$100.0K	$176.6K	$14.66K	$0.00
YoY Change	0.0%	-43.39%	1104.91%
Total Long-Term Assets	$3.133M	$2.780M	$3.190M	$1.403M	$1.490M	$950.0K	$1.010M	$1.070M	$1.130M	$1.130M	$1.400M	$0.00	$0.00	$0.00	$130.0K	$10.00K	$790.0K	$40.00K	$190.0K	$350.0K	$290.0K	$740.0K	$340.0K	$2.290M	$3.370M
YoY Change	12.7%	-12.85%	127.36%	-5.84%	56.84%	-5.94%	-5.61%	-5.31%	0.0%	-19.29%				-100.0%	1200.0%	-98.73%	1875.0%	-78.95%	-45.71%	20.69%	-60.81%	117.65%	-85.15%	-32.05%
Total Assets	$11.82M	$14.11M	$12.79M	$9.781M	$7.800M	$15.12M	$21.37M	$6.430M	$1.280M	$1.330M	$1.590M	$10.00K	$50.00K	$250.0K	$140.0K	$30.00K	$1.380M	$400.0K	$650.0K	$980.0K	$540.0K	$1.160M	$1.360M	$4.660M	$4.700M
YoY Change
Accounts Payable	$626.2K	$540.0K	$1.166M	$2.135M	$1.610M	$1.190M	$710.0K	$290.0K	$460.0K	$60.00K	$70.00K	$50.00K	$10.00K	$0.00	$60.00K	$50.00K	$1.380M	$1.240M	$890.0K	$970.0K	$380.0K	$220.0K	$50.00K	$240.0K	$340.0K
YoY Change	15.96%	-53.69%	-45.38%	32.6%	35.29%	67.61%	144.83%	-36.96%	666.67%	-14.29%	40.0%	400.0%		-100.0%	20.0%	-96.38%	11.29%	39.33%	-8.25%	155.26%	72.73%	340.0%	-79.17%	-29.41%
Accrued Expenses	$1.305M	$1.440M	$1.653M	$80.48K	$70.00K
YoY Change	-9.4%	-12.91%	1954.51%	14.97%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$100.0K	$60.00K	$0.00	$0.00	$0.00	$0.00	$30.00K	$40.00K	$0.00	$90.00K	$0.00
YoY Change														-100.0%	66.67%					-100.0%	-25.0%		-100.0%
Long-Term Debt Due					$70.00K											$0.00	$30.00K	$30.00K	$40.00K	$50.00K	$20.00K			$0.00	$660.0K
YoY Change																-100.0%	0.0%	-25.0%	-20.0%	150.0%				-100.0%
Total Short-Term Liabilities	$1.972M	$2.000M	$3.320M	$2.215M	$1.680M	$1.190M	$710.0K	$290.0K	$460.0K	$60.00K	$70.00K	$50.00K	$40.00K	$50.00K	$1.270M	$1.050M	$1.490M	$1.310M	$1.100M	$1.560M	$750.0K	$470.0K	$70.00K	$490.0K	$1.140M
YoY Change	-1.41%	-39.75%	49.84%	31.87%	41.18%	67.61%	144.83%	-36.96%	666.67%	-14.29%	40.0%	25.0%	-20.0%	-96.06%	20.95%	-29.53%	13.74%	19.09%	-29.49%	108.0%	59.57%	571.43%	-85.71%	-57.02%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$250.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$10.00K	$0.00	$0.00	$10.00K	$30.00K	$0.00	$0.00	$0.00	$1.370M
YoY Change				-100.0%												-100.0%			-100.0%	-66.67%				-100.0%
Other Long-Term Liabilities	$644.9K	$20.00K	$389.5K	$189.3K	$0.00											$0.00	$10.00K	$40.00K	$40.00K	$90.00K	$0.00	$450.0K	$0.00
YoY Change	3124.35%	-94.87%	105.77%													-100.0%	-75.0%	0.0%	-55.56%		-100.0%
Total Long-Term Liabilities	$644.9K	$20.00K	$389.5K	$189.3K	$250.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$20.00K	$40.00K	$40.00K	$100.0K	$30.00K	$450.0K	$0.00	$0.00	$1.370M
YoY Change	3124.35%	-94.87%	105.77%	-24.28%												-100.0%	-50.0%	0.0%	-60.0%	233.33%	-93.33%			-100.0%
Total Liabilities	$2.617M	$2.020M	$3.709M	$2.405M	$1.920M	$1.190M	$710.0K	$290.0K	$460.0K	$60.00K	$70.00K	$50.00K	$40.00K	$50.00K	$1.270M	$1.050M	$1.510M	$1.350M	$1.130M	$1.660M	$780.0K	$920.0K	$70.00K	$490.0K	$2.510M
YoY Change	29.54%	-45.54%	54.24%	25.24%	61.34%	67.61%	144.83%	-36.96%	666.67%	-14.29%	40.0%	25.0%	-20.0%	-96.06%	20.95%	-30.46%	11.85%	19.47%	-31.93%	112.82%	-15.22%	1214.29%	-85.71%	-80.48%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2024	2023	2022	2021
Basic Shares Outstanding	7.621M shares	2.448M shares	560.8K shares	268.8K shares
Diluted Shares Outstanding	7.621M shares	2.448M shares	560.8K shares	268.8K shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $3.236 Million

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc is a CA-based company operating in Pharmaceuticals industry. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2001-06-21. InMed Pharmaceuticals Inc. is a pharmaceutical company. The company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.

Industry: Pharmaceutical Preparations Peers: Pharmagreen Biotech Inc. Target Group Inc.